VeriSIM Life

VeriSIM Life is an AI-powered drug discovery company offering a machine learning-driven platform, BIOiSIM, which allows pharmaceutical companies and drug developers to conduct preclinical experiments using biosimulation models that reflect interactions between drugs and animals' biological systems. The platform can predict a potential drug’s response and clinical outcome without the need for actual animal testing, thereby reducing the cost and time spent on animal trials or even entirely eliminating them.

The company is also engaged in developing novel therapeutics through its subsidiary PulmoSIM Therapeutics, which leverages the BIOiSIM platform. PulmoSIM has two drug candidates in its pipeline targeting pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), both of which are in their preclinical stages. VeriSIM Life acquired Spanish biotechnology firm Molomics Biotech in May 2022, to integrate VeriSIM’s platform with Molomics’ Human Collective Intelligence (HCI) technology, enhancing the company’s ability to make successful clinical trial predictions.

In its latest Series A funding round in January 2022, VeriSIM Life raised USD 15 million, bringing the total funds it has raised to date to USD 21.7 million. VeriSIM intends to use the funding to accelerate its operational growth and platform development.